London Isomorphic Labs Raises $2.1 Billion Funding In Series B Round

The round was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

The company will use the funds to advance its AI drug design engine (IsoDDE), expand its therapeutic pipeline toward clinical trials, and scale its global team across AI, engineering, and clinical research.

Founded by Sir Demis Hassabis and led with President Max Jaderberg, Isomorphic Labs is building a unified AI-driven drug discovery platform that extends beyond AlphaFold to predict and design novel molecules across a range of diseases.

Read Also - Barcelona’s Dolfin Raises €2.1M Seed Round To Grow Its AI Sales Compensation Platform

The company aims to transform drug discovery into a data-driven engineering discipline, accelerating the development of new treatments.

It also collaborates with major pharmaceutical companies including Novartis, Eli Lilly, and Johnson & Johnson to validate and advance its AI-first approach.

“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,” said Max Jaderberg, President of Isomorphic Labs.

“Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.”

About Isomorphic Labs

Isomorphic Labs, founded in 2021, is an AI-first drug discovery company headquartered in London, with offices in Cambridge and Lausanne. Led by Sir Demis Hassabis and Max Jaderberg, it develops advanced AI models for drug design across multiple therapies and modalities, advancing both partnered and in-house programs to accelerate biomedical breakthroughs.